The Food and Drug Administration has hired Flatiron Health‘s Amy Abernethy as its principal deputy commissioner of food and drugs, according to an internal FDA memo that an agency spokeswoman forwarded to MedCity.
Pending ethics clearances, she will start her new position in the next few months.
Abernethy, an oncologist, currently serves as chief medical officer, chief scientific officer and senior vice president of oncology at Flatiron Health. The New York City company, which was acquired by Roche earlier this year, develops technology aimed at the cancer space. Its offerings include an EMR, practice management system, analytics solution and clinical trials tool.
Abernethy joined Flatiron in 2014. Previously, she was the director of the Duke Center for Learning Health Care and the Duke Cancer Care Research Program, according to her LinkedIn profile. She received her medical degree from Duke and currently serves on athenahealth’s board of directors.
“Dr. Abernethy brings to the FDA deep experience in evidence generation and clinical trial efficiency and innovation, which will help us advance our clinical policy and programs and continue to drive scientific excellence in support of FDA’s public health mission,” FDA Commissioner Scott Gottlieb wrote in the internal memo. “She has also put patients at the center of her work throughout her distinguished career.”
As the new principal deputy commissioner, Abernethy takes over for Rachel Sherman, who is retiring from her role. The position is the highest one at the FDA that is not politically appointed, according to Forbes.
Photo: SergeyNivens, Getty Images